MarketStudyReport.com adds “Global Gliclazide (CAS 21187-98-4) Market Outlook 2016-2021” new report to its research database. The report spread across 113 pages with table and figures in it.
Gliclazide (CAS 21187-98-4) is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. Its classification has been ambiguous, as literature uses it as both a first-generation and second-generation sulfonylurea. Gliclazide was shown to protect human pancreatic beta-cells from hyperglycemia-induced apoptosis. It was also shown to have an antiatherogenic effect (preventing accumulation of fat in arteries) in type 2 diabetes.
Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-gliclazide-cas-21187-98-4-market-outlook-2016-2021/
This report provides detailed analysis of worldwide markets for Gliclazide (CAS 21187-98-4) from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Gliclazide (CAS 21187-98-4) market and further lays out an analysis of the factors influencing the supply/demand for Gliclazide (CAS 21187-98-4), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Global Gliclazide (CAS 21187-98-4) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Gliclazide (CAS 21187-98-4) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Gliclazide (CAS 21187-98-4) market are Servier (France), CFM Group (Italy), Ningbo Double Sun (China), Shanghai Modern Hasen (China), Shandong Fangming (China), Jiuzhou Pharmaceutical (China), Keyuan Pharmaceutical (China), among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Gliclazide (CAS 21187-98-4) industry has been provided.
To receive personalized assistance, write to us @ firstname.lastname@example.org with the report title in the subject line along with your questions or call us at +1 866-764-2150